Current controversies in early-stage melanoma: Questions on management and surveillance

• Published in: Journal of the American Academy of Dermatology Vol. 80; no. 1; pp. 15 - 25
• Main Authors: Klapperich, Marki E, Bowen, Glen M, Grossman, Douglas
• Format: Journal Article
• Language: English
• Published: United States 01-01-2019
• Subjects: Humans; Melanoma - pathology; Melanoma - surgery; Neoplasm Staging; Population Surveillance; Skin Neoplasms - pathology; Skin Neoplasms - surgery; melanoma; surveillance; imaging; staging; transection
• ISSN: 1097-6787
• DOI: 10.1016/j.jaad.2018.03.054

There are a number of controversies and uncertainties relating to the management and surveillance of patients with early-stage, localized (ie, stage 0, I, and II) cutaneous melanoma. While tumor stage is a critical predictor of clinical outcome and guides treatment, accurate determination of stage may be affected by the biopsy technique used and the method of sectioning before histologic review. A new molecular prognostic test is available but has not been formally incorporated into staging or treatment guidelines. There are no randomized controlled clinical trials to support guidelines for surveillance following the treatment of early-stage melanoma. In the second article in this continuing medical education series, we review the controversies and uncertainties relating to these issues. The questions we address are controversial because they speak to clinical scenarios for which there are no evidence-based guidelines or randomized clinical trials with the consequence of considerable variability in clinical practice. Our goal is to provide the clinician with up-to-date contextual knowledge to appreciate the multiple sides of each controversy and to suggest pathways to resolution.